Petar M.

Research activities target B‑cell malignancies including chronic lymphocytic leukemia, multiple myeloma, and non‑Hodgkin lymphoma, with a focus on infection risk and novel immunotherapies.

• Prevention of infections in patients with hypogammaglobulinemia
• Combination strategies with BTK inhibitors
• Evaluation of B‑cell directed biologics
• Monitoring disease progression and response
• Safety profiling of emerging agents

Efforts address the immunodeficiency challenges inherent to these cancers.

The investigator explores therapies for heart failure, atherosclerotic cardiovascular disease, chronic kidney disease and hypertension, seeking integrated cardio‑renal benefits.

• Efficacy of SGLT2‑inhibitor combinations
• Reduction of major adverse cardiovascular events
• Strategies to lower albuminuria
• Targeting lipoprotein(a) to prevent first cardiovascular events
• Assessment of overall cardioprotective outcomes

Renal function preservation is a central component of the research.

Studies address allergic diseases such as birch pollen‑induced rhinoconjunctivitis and chronic spontaneous urticaria, focusing on symptom control and quality of life.

• Immunotherapy for birch pollen allergy
• Improvement of urticaria activity scores
• Biologic modulation of IgE pathways
• Assessment of patient‑reported symptom relief
• Pediatric allergy management strategies

Outcomes emphasize measurable reductions in daily symptom burden.

Investigation of novel cytokine inhibitors and pathway‑targeted agents, including anti‑IL‑33, anti‑IL‑17, and JAK inhibitor therapies such as ritlecitinib, spans multiple disease areas.

• Anti‑IL‑33 and anti‑IL‑17 therapeutic potential
• Clinical safety of JAK inhibitor ritlecitinib
• Evaluation of anti‑TSLP agents
• Application in severe asthma
• Broad anti‑inflammatory effects across indications

Research seeks cross‑disease applicability of these immune‑targeted treatments.